Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | CMV treatment for stem cell transplant recipients: antivirals

Genovefa Papanicolaou • 18 Mar 2018
EBMT 2018
General Foscarnet Ganciclovir Letermovir Maribavir Valganciclovir

Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the current and future developments in the treatment of a particularly dangerous viral infection, cytomegalovirus (CMV). This interview was conducted at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

More from Genovefa Papanicolaou

1:06
Vaccines for the treatment of CMV in stem cell transplant recipients
Genovefa Papanicolaou • 18 Mar 2018
1:07
Preventing cytomegalovirus (CMV) infections in patients receiving bone marrow transplants
Genovefa Papanicolaou • 2 Dec 2016

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals